OptimizeRx (NASDAQ:OPRX) Stock Price Target Lowered at Stifel Nicolaus

OptimizeRx (NASDAQ:OPRX) had its price target cut by research analysts at Stifel Nicolaus from $12.00 to $11.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus‘s price objective indicates a potential upside of 22.91% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Citizens Jmp boosted their price target on shares of OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Friday, August 14th. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a report on Tuesday, October 27th. UBS Group set a $11.00 target price on OptimizeRx in a report on Friday, August 14th. Weiss Ratings raised OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, August 25th. Finally, Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.43.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $8.95 on Thursday. The company has a market capitalization of $168.62 million, a P/E ratio of 38.91 and a beta of 1.20. OptimizeRx has a fifty-two week low of $4.54 and a fifty-two week high of $16.37. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.58 and a current ratio of 5.58. The stock has a 50 day moving average price of $8.43 and a two-hundred day moving average price of $7.24.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Wednesday, November 11th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.16 by $0.04. The company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $21.19 million. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. Analysts expect that OptimizeRx will post 0.49 earnings per share for the current year.

Institutional Investors Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in OptimizeRx by 633.2% in the 1st quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock valued at $1,362,000 after acquiring an additional 187,278 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in OptimizeRx during the 1st quarter valued at $1,185,000. AWM Investment Company Inc. bought a new stake in shares of OptimizeRx in the 2nd quarter worth $1,375,000. Dimensional Fund Advisors LP increased its holdings in shares of OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after purchasing an additional 102,661 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of OptimizeRx by 131.7% in the 1st quarter. Principal Financial Group Inc. now owns 63,790 shares of the company’s stock worth $401,000 after purchasing an additional 36,259 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.